ES2534419T3 - Utilización de anticuerpos contra un antígeno asociado con un tumor - Google Patents

Utilización de anticuerpos contra un antígeno asociado con un tumor Download PDF

Info

Publication number
ES2534419T3
ES2534419T3 ES03783820.8T ES03783820T ES2534419T3 ES 2534419 T3 ES2534419 T3 ES 2534419T3 ES 03783820 T ES03783820 T ES 03783820T ES 2534419 T3 ES2534419 T3 ES 2534419T3
Authority
ES
Spain
Prior art keywords
tumor
preparation
antibodies against
antigen associated
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03783820.8T
Other languages
English (en)
Spanish (es)
Inventor
Hans Loibner
Gottfried Himmler
Hellmut Samonigg
Eugen Stermetz
Andreas Hauer
Gerda Redl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meridian Biopharmaceuticals GmbH
Eleva GmbH
Original Assignee
Meridian Biopharmaceuticals GmbH
Greenovation Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meridian Biopharmaceuticals GmbH, Greenovation Biotech GmbH filed Critical Meridian Biopharmaceuticals GmbH
Application granted granted Critical
Publication of ES2534419T3 publication Critical patent/ES2534419T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES03783820.8T 2002-08-12 2003-07-31 Utilización de anticuerpos contra un antígeno asociado con un tumor Expired - Lifetime ES2534419T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT12172002 2002-08-12
AT0121702A AT413487B (de) 2002-08-12 2002-08-12 Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
PCT/AT2003/000219 WO2004014421A1 (de) 2002-08-12 2003-07-31 Verwendung von antikörpern gegen ein tumor-assoziiertes antigen

Publications (1)

Publication Number Publication Date
ES2534419T3 true ES2534419T3 (es) 2015-04-22

Family

ID=31499792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03783820.8T Expired - Lifetime ES2534419T3 (es) 2002-08-12 2003-07-31 Utilización de anticuerpos contra un antígeno asociado con un tumor

Country Status (8)

Country Link
US (1) US20060127403A1 (de)
EP (1) EP1528934B1 (de)
AT (1) AT413487B (de)
AU (1) AU2003250570B2 (de)
CA (1) CA2494319A1 (de)
DK (1) DK1528934T3 (de)
ES (1) ES2534419T3 (de)
WO (1) WO2004014421A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
EP2033657A1 (de) * 2007-09-04 2009-03-11 Trion Pharma Gmbh Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination
KR20230030626A (ko) 2020-06-30 2023-03-06 글리코토페 게엠베하 루이스 y에 대한 인간화된 항체

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643971A (en) * 1983-03-11 1987-02-17 Sloan-Kettering Institute Monoclonal antibodies to human bladder and ureter cancers and method
DE69230545T2 (de) 1991-08-21 2000-07-06 Novartis Ag, Basel Antikörperderivate
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
JPH08500335A (ja) * 1992-05-06 1996-01-16 イムノメディクス，インコーポレイテッド 手術，血管内手技または内視鏡手技における腫瘍および病変の検出と治療
WO1994021293A1 (en) * 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US6495129B1 (en) * 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
DK1187632T3 (da) * 1999-05-14 2009-04-06 Genentech Inc Behandling med anti-ErbB2-antistoffer
WO2001003738A1 (fr) * 1999-07-07 2001-01-18 Hiroshi Maeda Agents de type polymeres destines a la prevention de metastases et de la recurrence du cancer et methode de prevention de metastases et de la recurrence du cancer
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
US20040142381A1 (en) * 2002-07-31 2004-07-22 Hubbard Stevan R. Methods for designing IGF1 receptor modulators for therapeutics

Also Published As

Publication number Publication date
US20060127403A1 (en) 2006-06-15
AU2003250570A1 (en) 2004-02-25
CA2494319A1 (en) 2004-02-19
AU2003250570B2 (en) 2009-10-22
WO2004014421A1 (de) 2004-02-19
ATA12172002A (de) 2005-08-15
DK1528934T3 (en) 2015-04-13
AT413487B (de) 2006-03-15
EP1528934B1 (de) 2015-01-07
EP1528934A1 (de) 2005-05-11

Similar Documents

Publication Publication Date Title
ES2528384T3 (es) Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
ES2539133T3 (es) Dispositivo para mejorar la función de la válvula cardiaca
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
Hyun Prostate cancer and sexual function
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
CY1109402T1 (el) Συνθεσεις για κολπικη χρηση
RU2009101324A (ru) Композиции и способы лечения воспаления слизистой оболочки
US20180125975A1 (en) Emissive polymeric matrices
ES3015668T3 (en) Neoadjuvant therapy for bladder cancer
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
ES2534419T3 (es) Utilización de anticuerpos contra un antígeno asociado con un tumor
ES2910034T3 (es) Procedimiento de fototerapia dinámica (FTD) para el cáncer de vejiga
AR022937A1 (es) Celulas mamiferas conjugadas con haptenos y metodos para su constitucion y uso
Herr Transurethral resection in regionally advanced bladder cancer
UY28457A1 (es) Nueva composición
ES2486844T3 (es) Sustancia que presenta propiedad antidepresiva
ES2561291T3 (es) Tratamiento de enfermedades
Cusini et al. Atypical early syphilis in an HIV-infected homosexual male
Kaufmann The concept of field cancerization
Spiers et al. An epidermal proliferative reaction associated with a silicone gel breast implant
CO5611170A2 (es) Uso de un inhibidor antagonista contra el factor tisular
RU2297823C1 (ru) Способ лечения больных гормональнозависимыми заболеваниями
Carbinatto et al. Photodynamic therapy of Cervical Intraepithelial Neoplasia (CIN) high grade